At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AEMD Aethlon Medical
Closed Good Friday 04-17 16:00:00 EDT
0.3590
+0.0078
+2.22%
盘后0.3600
+0.0010+0.28%
17:21 EDT
| High0.3699 | Low0.3427 | Vol46.88K |
| Open0.3500 | D1 Closing0.3512 | Amplitude7.74% |
| Mkt Cap7.42M | Tradable Cap7.10M | Total Shares20.66M |
| T/O16.70K | T/O Rate0.24% | Tradable Shares19.77M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now
GlobeNewswire · 03-26
Aethlon Medical Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03-10
Buy Rating for Aethlon Medical Driven by Hemopurifier’s Potential in Organ Transplantation and Projected Growth
TIPRANKS · 03-10
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal
PR Newswire · 03-10
Aethlon Medical Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 02-19
Q3 2025 Aethlon Medical Inc Earnings Call
Thomson Reuters StreetEvents · 02-13
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
PR Newswire · 02-13
AEMD: Patient Enrollments in Oncology Trial Expected to Accelerate With 3rd Participating Site, Protocol Amendments
Zacks Small Cap Research · 02-13
Aethlon Medical Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 02-12
Aethlon Medical Q3 EPS $(0.13) Beats $(0.20) Estimate
Benzinga · 02-12
Aethlon Medical reports Q3 EPS (13c), consensus (20c)
TIPRANKS · 02-12
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
PR Newswire · 02-12
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones · 02-12
Aethlon Medical Inc expected to post a loss of 21 cents a share - Earnings Preview
Reuters · 02-10
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
PR Newswire · 02-05
Aethlon Medical Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 01-30
AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of Hemopurifier
Zacks Small Cap Research · 01-30
BRIEF-Aethlon Advances Hemopurifier® Study In Solid Tumors Not Responding To Anti-PD-1 Antibodies
Reuters · 01-29
Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial
THOMSON REUTERS · 01-29
Aethlon Medical : Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-Pd-1 Antibodies
THOMSON REUTERS · 01-29
Introduction
Company Name.
Aethlon Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App